Abstract
6096 Background: Approximately 20% of pts with LA, HPV+ OPSCC have poor survival outcomes. To date, there is a paucity of biomarkers to predict which pts will ultimately fail standard therapy. E6/E...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
